Heads up! Predictive gene signatures in head and neck cancer may be coming soon

  • Chau N
  • Hammerman P
  • 11


    Mendeley users who have this article in their library.
  • 1


    Citations of this article.


Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 1-3. ©2016 AACR.See related article by Bossi et al., p. 3961.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Nicole G. Chau

  • Peter S. Hammerman

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free